Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 11/20 | 0.65 |
| ▸ | CDK4 | P11802 | 2/20 | 0.57 |
| ▸ | CCND1 | P24385 | 2/20 | 0.57 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1435516 | 1.00 | NFE2L2 (0.65) | NFE2L2CDK4CCND1TRPA1ALDH1A1 | |
| SCHEMBL29405542 | 1.00 | NFE2L2 (0.65) | NFE2L2CDK4CCND1TRPA1ALDH1A1 | |
| SCHEMBL16476616 | 0.83 | CDK4 (0.70) | NFE2L2CDK4CCND1TRPA1ALDH1A1 | |
| SCHEMBL11070320 | 0.83 | CDK4 (0.70) | NFE2L2CDK4CCND1TRPA1ALDH1A1 | |
| SCHEMBL1399255 | 0.83 | CDK4 (0.48) | NFE2L2CDK4CCND1TRPA1ALDH1A1 | |
| SCHEMBL3720641 | 0.83 | CDK4 (0.48) | NFE2L2CDK4CCND1TRPA1ALDH1A1 | |
| SCHEMBL2234105 | 0.80 | NFE2L2 (1.00) | NFE2L2MAOB | |
| SCHEMBL16933870 | 0.77 | NFE2L2 (0.65) | NFE2L2MAOB | |
| SCHEMBL16933866 | 0.77 | NFE2L2 (0.65) | NFE2L2MAOB | |
| SCHEMBL1759676 | 0.76 | NFE2L2 (0.56) | NFE2L2ALDH1A1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118859629-B | Water-soluble photosensitive composite dry film and preparation method thereof | 广东泰亚达光电有限公司 | 2024-12-20 | — | — | CN | claimed |
| CN-116855966-A | Electrocatalytic preparation method of cinnamaldehyde and derivative thereof | 湖南大学 | 2023-10-10 | — | — | CN | disclosed |
| CN-107827852-B | Patchoulenone derivative and preparation method and application thereof | 成都中医药大学 | 2021-08-20 | — | — | CN | disclosed |
| CN-108558851-B | Coumarin-oxazole-ethylene type alpha-glucosidase inhibitor and preparation method and application thereof | 贵州医科大学 | 2021-03-05 | — | — | CN | disclosed |
| CN-106852143-B | Tricyclic triazolic compounds | 埃斯蒂维制药股份公司 | 2019-07-16 | — | — | CN | disclosed |
| US-9776979-B2 | EBI2 modulators | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-10-03 | — | — | US | disclosed |
| CN-106852143-A | Tricyclic triazolic compounds | 埃斯蒂维实验室股份有限公司 | 2017-06-13 | — | — | CN | disclosed |
| US-20160214951-A1 | EBI2 MODULATORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2016-07-28 | — | — | US | disclosed |
| CN-103724357-B | The synthetic method of a kind of 3,4-dihydropyrane also [3,2-b] indole-2-ketone compound | 中国药科大学 | 2016-06-08 | — | — | CN | disclosed |
| US-8558012-B2 | 2-fluoro-1,3-benzodithiol 1,1,3,3-tetraoxide derivative, production method thereof, and production method of monofluoromethyl group-containing compound using the same | NAGOYA INSTITUTE OF TECHNOLOGY (JP) | 2013-10-15 | — | — | US | disclosed |
| US-8513258-B2 | Cinnamoyl-piperazine derivatives and their use as par-1 antagonists | PIERRE FABRE MEDICAMENT (FR) | 2013-08-20 | — | — | US | disclosed |
| US-20120232097-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | PEREZ MICHEL (FR) | 2012-09-13 | — | — | US | disclosed |
| US-8217046-B2 | Cinnamoyl-piperazine derivatives and their use as PAR-1 antagonists | PIERRE FABRE MEDICAMENT (FR) | 2012-07-10 | — | — | US | disclosed |
| US-20110319637-A1 | 2-FLUORO-1,3-BENZODITHIOL 1,1,3,3-TETRAOXIDE DERIVATIVE, PRODUCTION METHOD THEREOF, AND PRODUCTION METHOD OF MONOFLUOROMETHYL GROUP-CONTAINING COMPOUND USING THE SAME | NAGOYA INSTITUTE OF TECHNOLOGY (JP) | 2011-12-29 | — | — | US | disclosed |
| EP-1898908-B1 | NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICAMENT | TROPHOS (FR) | 2011-03-30 | — | — | EP | disclosed |
| US-20090203747-A1 | NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICINE | TROPHOS PARC SCIENTIFIQUE LUMINY (FR) | 2009-08-13 | — | — | US | disclosed |
| US-20090176803-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2009-07-09 | — | — | US | disclosed |
| EP-1898908-A2 | NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICAMENT | Trophos (FR) | 2008-03-19 | — | — | EP | disclosed |
| CN-101076332-A | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases | PTC THERAPEUTICS INC (US) | 2007-11-21 | — | — | CN | disclosed |
| WO-2007003767-A2 | NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICINE | TROPHOS (FR) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176803-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | F2R, F2RL1, F2RL3 | NFE2L2 1258/4885CDK4 1473/4885CCND1 1155/4885 |
| US-20110319637-A1 | 2-FLUORO-1,3-BENZODITHIOL 1,1,3,3-TETRAOXIDE DERIVATIVE, PRODUCTION METHOD THEREOF, AND PRODUCTION METHOD OF MONOFLUOROMETHYL GROUP-CONTAINING COMPOUND USING THE SAME | CBR1, CYP1B1, CYP2F1 | NFE2L2 364/4885CDK4 4068/4885CCND1 1963/4885 |
| US-20120232097-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | F2R, F2RL1, F2RL3 | NFE2L2 1258/4885CDK4 1473/4885CCND1 1155/4885 |
| US-20160214951-A1 | EBI2 MODULATORS | BIRC2, HAVCR2, MAVS | NFE2L2 1484/4885CDK4 1329/4885CCND1 3851/4885 |
| US-20090203747-A1 | NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICINE | NLN, NQO1, APP | NFE2L2 83/4885CDK4 2972/4885CCND1 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.